Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
CARLSBAD, Calif., April 24, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group. The positive results are being presented today in an Emerging Science Session at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston. ATTRv-PN is a debilitating disease driven by the progressive accumulation of TTR amyloid deposits, which causes progressive nerve damage and leads to organ failure and eventually death.
myBinderRelated Content
-
Finding a Clinical TrialNIH conducts clinical research trials fo...
-
Learn About Clinical StudiesWhat Is a Clinical Study? A clini...
-
Informed Consent for Clinical TrialsThe term informed consent is mistakenl...
-
Progress in Amyloidosis Research: Where Are We Now? – Webinarhttps://www.youtube.com/watch?v=8Yhv87Xo...
-
Amyloid Pathology Transmission in Lab Mice and Historic Medical TreatmentsA UCL-led study has confirmed that som...
-
Introduction & Discussion: Andromeda Drug Trial (daratumumab) and Related Topicshttps://www.youtube.com/watch?v=PYbsAmtZ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
